IP Library › Granted Patent US 12,000,834
Granted Patent B2
US 12,000,834 · App. 16/762,976 · Granted Jun 4, 2024

Methods and materials for assessing and treating cancer

Inventors: Luz M. Cumba-Garcia (Rochester, MN); Ian F. Parney (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
G01N33/57488G01N33/53G01N33/56966G01N33/574G01N33/6863G01N2333/5428G01N2333/5437G01N2333/57G01N2333/70532G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,000,834
App. No.
16/762,976
Granted
Jun 4, 2024
Kind
B2
Abstract

This document relates to methods and materials for identifying and/or treating mammals having cancer. For example, small extracellular vesicles (EVs), such as exosomes, obtained from a mammal suspected of having a cancer can be used to identify the mammal as having cancer and, optionally, the mammal can be treated.

Claims (11)

1. A method for treating a mammal having glioblastoma cancer, wherein said method comprises:

(a) identifying extracellular vesicles (EVs) in a sample from said mammal, wherein said EVs have reduced levels of one or more immunomodulatory polypeptides as compared to a sample obtained from a mammal not having said cancer, wherein said one or more immunomodulatory polypeptides is selected from IFN-γ, IL-10, IL-13, CD80, CD86, and ICOSL; and

(b) administering a cancer treatment to said mammal having cancer, wherein said cancer treatment is selected from the group consisting of surgery, radiation therapy, chemotherapy, tumor treating fields (TTF) therapy, targeted therapy, hormone therapy, angiogenesis inhibitor therapy, tumor vaccination, checkpoint blockade therapy, and any combinations thereof.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said sample is a blood sample.

4. The method of claim 1 , wherein said EVs are exosomes.

5. The method of claim 4 , wherein the longest diameter of said exosomes is less than about 100 nm.

6. A method for treating glioblastoma cancer, wherein said method comprises administering a cancer treatment to a mammal having cancer and identified as having extracellular vesicles (EVs) having a reduced level of one or more immunomodulatory polypeptides as compared to the level of said one or more immunomodulatory polypeptides present in EVs obtained from a control mammal not having said cancer, wherein said one or more immunomodulatory polypeptides is selected from IFN-γ, IL-10, IL-13, CD80, CD86, and ICOSL, and wherein said cancer treatment is selected from the group consisting of surgery, radiation therapy, chemotherapy, tumor treating fields (TTF) therapy, targeted therapy, hormone therapy, angiogenesis inhibitor therapy, tumor vaccination, checkpoint blockade therapy, and any combinations thereof.

7. The method of claim 6 , wherein said mammal is a human.

8. The method of claim 6 , wherein said EVs are exosomes.

9. The method of claim 8 , wherein the longest diameter of said exosomes is less than about 100 nm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2021
From: CUMBA-GARCIA, LUZ M.; PARNEY, IAN F.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 055439/0015 →
Continuity (2)
Provisional Application 62584291 · Nov 10, 2017
Related Publication 20200271656A1 · Aug 27, 2020